



JPEO-CBRND CAPABILITIES CATALOG



FEBRUARY
2021

TABLE OF CONTENTS

| | |
|--|----|
| Mission and Vision | 4 |
| Message from the Joint Program Executive Officer | 5 |
| Leadership Biographies | 6 |
| Joint Project Manager (JPM) Descriptions | 10 |
| Joint Project Lead (JPL) Descriptions | 11 |
| Organization Leadership Chart | 12 |
| Strategic Objectives and Alignment | 13 |
| JPM CBRN Protection Capabilities | 14 |
| JPM CBRN Medical Capabilities | 19 |
| JPM CBRN Sensors Capabilities | 24 |
| JPL CBRN SOF Capabilities | 31 |
| JPL CBRN IM/IT Capabilities | 33 |
| JPL CBRND Enabling Biotechnologies Capabilities | 35 |
| Legacy and Sustainment Capabilities | 37 |
| Acronym List | 43 |



JPEO-CBRND MISSION AND VISION




OUR MISSION

Protect the Joint Force from weapons of mass destruction by generating affordable capabilities.



OUR VISION

A resilient Joint Force enabled to fight and win unencumbered by a chemical, biological, radiological, or nuclear environment; championed by innovative, agile, results-oriented acquisition professionals.





A NOTE FROM **DR. JASON ROOS**

Because we are a component of the Chemical and Biological Defense Program, the Joint Program Executive Office for Chemical, Biological, Radiological and Nuclear Defense (JPEO-CBRND) supports the entire Joint Force by developing solutions that enable our Warfighters to fight and win in a chemical, biological, radiological, or nuclear (CBRN) environment. The JPEO-CBRND leads, manages, and directs the acquisition and fielding of CBRN sensors, protective equipment, medical countermeasures, information management systems, defense-enabling biotechnologies, and specialized equipment for US Special Forces.

We are structured into portfolios that focus on CBRN protection, medical, and sensors. This construct allows us greater flexibility in aligning resources to goals and balancing risk against performance. These core focus areas contribute to building a more lethal force, a priority in the National Defense Strategy, and streamline JPEO-CBRND efforts to meet current Joint Service needs and plan for future requirements.

The JPEO-CBRND's three Joint Project Managers (JPM) provide oversight for the portfolios, including JPM CBRN Protection, JPM CBRN Medical and JPM CBRN Sensors. Our three Joint Project Leads (JPL) provide portfolio-wide enabling support across the organization in the areas of Special Operations Forces, Information Management/Information Technology, and Enabling Biotechnologies.

Our ability to meet our mission in the face of an ever-evolving threat landscape requires flexibility, speed, and agility-and we can't do it alone. Our partnerships with government, academia, industry, and international allies make it possible for us to push the boundaries of innovation, to shorten the time it takes to get new capabilities into Warfighters' hands, and to make sure we're operating as efficiently as possible.

As we face down the COVID-19 pandemic, and all the lessons we've learned about CBRN defense while supporting the national response, it was the JPEO-CBRND's ability to be agile and efficient that allowed us to accomplish our mission. I look forward to carrying that flexibility and adaptability into our future so we can best serve the Joint Force.



Dr. Jason W. Roos
Joint Program Executive Officer for Chemical,
Biological, Radiological and Nuclear Defense



LEADERSHIP BIOGRAPHIES

FOR MORE INFORMATION CALL 410-436-9000



DR. JASON W. ROOS

Dr. Roos serves as Joint Program Executive Officer for Chemical, Biological, Radiological and Nuclear Defense. He provides management and technical direction to the entire portfolio and leads civilian and military multi-disciplinary teams whose mission is to protect the U.S. Joint Forces and nation from CBRN threats. As a career Army acquisition professional and Ph.D. scientist, he brings a unique blend of acquisition, technical and business expertise to JPEO-CBRND.

Dr. Roos engages with Congress, the US Army and other Department of Defense organizations on CBRN defense program management and execution. He interfaces with the science and technology (S&T) community, and coordinates CBRN defense technology needs with DoD S&T agencies, interagency elements, international partners and industry.

Dr. Roos previously held numerous management positions within JPEO-CBRND, leading innovation and reform in CBRN defense acquisition. He was Director of the Biosurveillance Management Office (BMO), managing a portfolio of programs to field capabilities to enable early detection and warning of global health threats. He led the Joint Product Management Office for Biosurveillance—Provisional where he conducted total life cycle management of the Joint Biological Agent Identification and Diagnostic System, the Next Generation Diagnostic System and the Critical Reagents Program.

Dr. Roos holds a Bachelor's in chemistry from College of the Holy Cross; a Ph.D. in Biochemistry, Cellular and Molecular Biology from Johns Hopkins University School of Medicine; and a Master's in National Resource Strategy from National Defense University. He is a Certified Acquisition Professional.



MR. DANIEL J. MCCORMICK

Mr. McCormick is the Deputy Joint Program Executive Officer for Chemical, Biological, Radiological and Nuclear Defense (Acting). In this role, he leverages an extensive background and significant experience in the Chemical and Biological Defense Program. He helps ensure JPEO-CBRND programs are synchronized, prioritized and balanced to effectively integrate technologies in support of delivering CBRN defense capabilities to the Warfighter and nation.

Mr. McCormick's work experience includes more than 28 years of service as an Army officer and more than 20 years of acquisition experience. Prior to his current assignment, Mr. McCormick served JPEO-CBRND as Acting Deputy, Deputy Chief of Staff for Strategic Portfolio Integration and Special Assistant for Acquisition Integration. Mr. McCormick also served JPEO-CBRND as a Joint Project Manager responsible for the development, manufacture, test, fielding and life-cycle management of Department of Defense nuclear, chemical and biological

defense programs. During his tenure as Joint Project Manager for Nuclear Biological and Chemical Contamination Avoidance, then Colonel McCormick deployed to Afghanistan to lead planning, establishment and execution of Afghan Public Protection Force efforts in direct support of the Commander, International Security Assistance Force.

Mr. McCormick's acquisition assignments included Test Director for Future Combat Systems; Director of Plans, Programs and Resources for the Office of the Assistant Secretary of the Army; and the Joint Project Manager for Nuclear, Biological, Chemical Reconnaissance and Obscuration Systems. He had numerous other acquisition and tactical field artillery assignments during his Army career. He is a member of the Acquisition Corps and is Level III certified in Program Management. He holds a Master's degree from Naval War College and George Mason University, and a Bachelor's degree from Florida Institute of Technology.



MS. NICOLE R. KILGORE

Ms. Nicole Kilgore is the Deputy Joint Program Executive Officer for Operations and Modernization. In this role, she provides expert advice to the JPEO, JPMs, and JPLs across the portfolio; focuses primarily on the Medical and Protection portfolios; and monitors policies and project/products that deal with challenging acquisition problems to effectively deliver CBRN defense capabilities to the Warfighter and the Nation. In addition, Ms. Kilgore leads coordination of JPEO's COVID acquisition efforts.

Most recently, Ms. Kilgore was Deputy Joint Project Manager for JPM CBRN Medical where she provided overall direction and guidance for the development, acquisition, testing, product improvements, fielding, and sustainment of the Medical portfolio. She directed and coordinated planning for diverse projects, evaluated program results, and rendered final decisions.

Ms. Kilgore's assignments included several positions of increasing responsibility at JPM CBRN Medical, including Chief of Staff; Joint Product Lead, Platforms for Rapid Integrated

Solutions for Medical Countermeasures; Joint Product Manager and Deputy Joint Product Manager, Joint Vaccine Acquisition Program; Primary Manager, Filovirus Vaccine Program; and Science Manager, Medical Identification and Treatment Systems. She also previously served as Acting Medical Director, Office of Deputy Assistant Secretary of Defense for Chemical and Biological Defense.

Ms. Kilgore holds a Bachelor of Science in Biology from Mount Saint Mary's College; a Master of Science in Biomedical Sciences from Hood College; and Master of Science in National Resource Strategy from the National Defense University, Eisenhower School. She attended the Defense Acquisition University's Advanced Program Management Course and Advanced Leadership Course at the Army Management Staff College.

She is a member of the Army Acquisition Corps, DAWIA Level III certified in Program Management, and a Project Management Professional.



MR. GORDON L. GRAHAM

Mr. Gordon Graham is Chief of Staff for the Joint Program Executive Office for Chemical, Biological, Radiological and Nuclear Defense (JPEO-CBRND). In this role, he provides expertise in acquisition, budget, program management, and directorate staff management. Mr. Graham works across functional areas to build consensus and ensure JPEO CBRND programs have the resources required to support delivery of CBRN defense capabilities to the Warfighter and the nation.

Mr. Graham's work experience includes 29 years of combined acquisition and program management experience gained during active duty and civilian service. He was commissioned from the Reserve Officer Training Corps at The University of North Carolina Wilmington in 1988. He was a Distinguished Military Graduate and received a Bachelor of Arts in Psychology. Mr. Graham also holds a Master of Science in General Administration from Central Michigan University and a Master of Arts in Procurement

and Acquisition Management from Webster University. His military education includes the Ordnance Officers' Basic Course; the Combined Logistics Officers' Advanced Course; the U.S. Navy Explosive Ordnance Disposal Course; the Combined Arms and Services Staff School Course; Army Command and General Staff College; and Defense Systems Management College Program Manager's Course. He is currently Level III certified in Program Management.

Mr. Graham's military awards include the Legion of Merit Medal & Award presented at his retirement. Other awards include the Bronze Star; Defense Meritorious Service Medal (two oak leaf clusters); Army Meritorious Service Medal (three oak leaf clusters); Army Commendation Medal (four oak leaf clusters); Army Achievement Medal (two oak leaf clusters); Army Basic Airborne and EOD Badges; and Office of the Secretary of Defense Staff Badge.



MS. EMMA WILSON

Ms. Wilson has served as the Assistant Joint Program Executive Officer since April 2020. She has extensive experience developing and leading teams in a range of complex environments. She has proven experience in acquisition and logistics, management and business operations, planning and executing complex operations.

Prior to her current assignment, Ms. Wilson spent the past ten years leading planning and transformation actions to achieve a more agile and responsive staff capability within the JPEO-CBRND. Her prior roles within the JPEO-CBRND included Joint Product Lead for CBRN Portfolio Resources, Acting Joint Product Manager Guardian, Deputy Chief of Staff for Support Operations, Acting Chief of Staff, Assistant Chief of Staff, Deputy Chief of Staff for Policy and Strategic Initiatives, Director of Strategic Concepts and Technology, and Deputy Director for Future Acquisition. Prior to joining JPEO-CBRND, Ms. Wilson served as Executive Officer to the Office Deputy Assistant Secretary of the Army for Acquisition Policy and Logistics.

Before beginning her civilian service career, Ms. Wilson completed a successful 20 year career as an officer in the United States Army. Her assignments included Senior Acquisition Logistician in the Office of the Deputy Assistant Secretary of the Army (Integrated Logistics Support); Chief G3 Exercises, Signal Corps, 1st Infantry Division in Wurzburg, Germany; Deputy G6, 1st Infantry Division in Wurzburg, Germany; Executive Officer, 1/48 Infantry Battalion, 3rd Training Brigade at Fort Leonard Wood, MO; Signal Branch Advisor, Readiness Group at Fort Leonard Wood, MO; and Company Grade Signal Officer, U.S. Army.

Ms. Wilson earned a BA in history from Eastern Washington University, an MPA from the University of Oklahoma, and an MS from Industrial College of the Armed Forces, National Defense University. She also completed the Harvard Kennedy School of Government's Senior Executive Fellows program. Ms. Wilson is certified Defense Acquisition Workforce Improvement Act (DAWIA) Level III in Program Management and Life Cycle Management.



COLONEL SEAN MCMURRY

COL Sean A. McMurry is a graduate of the Virginia Military Institute and was commissioned in the US Army Medical Service Corps. He holds an MBA from Mount Saint Mary's University. He is a member of the Army Acquisition Corps with a Level III certification in Program Management, Contracting, and Life Cycle Logistics.

COL McMurry served in various leadership and command positions to include: US Department of Health and Human Services Fellow, Joint Product Manager, CBRNE Analytics and Response Systems; Executive Officer, 6th Medical Logistics Management Center, Fort Detrick, Maryland; Chief, Distribution and Transportation, US Army Medical Materiel Center Europe, Pirmasens, Germany; Chief, Materiel Management Division, Pirmasens, Germany; Chief, European Region Contracting Office, Landstuhl; Germany; Executive Officer, Medical Research Acquisition

and Contracting Activity; Medical Operations Officer, 7th Special Forces Group (A), Fort Bragg, North Carolina; J-35 Medical Plans Officer, CJSOTF-A, Afghanistan; Chief, Medical Logistics, US Army Special Operations Command (A), Fort Bragg, North Carolina; Aide-de Camp, Pacific Regional Medical Commander, Honolulu, Hawaii; Company Commander, Tripler Army Medical Center; and many others.

He is a graduate of the AMEDD Officer Basic and Advance Course, US Army Command and General Staff College, Medical Logistics Officers Course, Special Operations Staff Course, US Army Airborne School, US Army Air-Assault School, US Army Pathfinder Course, and US Army Jumpmaster School. He completed the Program Managers Executive Course, the Pre-Command Course, and the US Army War College.

JOINT PROJECT MANAGER (JPM) DESCRIPTIONS



JPM CBRN PROTECTION

JPM CBRN Protection develops, fields and sustains CBRN protection and increases mitigation capabilities for the Nation. Their focus in coordination with JPL CBRN Special Operations Forces is to unencumber the warfighter by developing a next-generation protective ensemble that reduces the physiological burden on the user and enhances protection to emerging threats. They also focus on developing contamination mitigation technologies including decontamination systems, protective coatings and barriers to significantly decrease the time required to decontaminate and reset personnel and equipment in CBRN environments.



JPM CBRN MEDICAL

JPM CBRN Medical facilitates the advanced development and acquisition of medical solutions to combat CBRN and emerging threats. Their focus in coordination with JPL Enabling Biotechnologies is to provide new and improved medical countermeasures to enable a single treatment for many threats, rapid medical countermeasure responses, genomic sequencing and the capability to diagnose CBRN threats before the onset of symptoms.



JPM CBRN SENSORS

JPM CBRN Sensors develops, fields and sustains CBRN sensors, reconnaissance systems, mobile laboratory systems and obscuration capabilities. Their focus in coordination with JPL Information Management/Information Technology is to provide integrated early warning by bringing together the products in its portfolio along with robotics and autonomous systems, decision support tools, machine learning and artificial intelligence to provide situational awareness and understanding of CBRN threats.

JOINT PROJECT LEAD (JPL) DESCRIPTIONS



JPL CBRN SPECIAL OPERATIONS FORCES (JPL CBRN SOF)

JPL CBRN SOF rapidly acquires and equips Special Operation and Special Purpose Forces with critical, capability-gap-filling, chemical, biological, radiological and nuclear defense equipment necessary to underwrite mission success. CBRN SOF's focus is to further develop crucial technologies necessary to the survival and unimpeded employment of special operations forces in toxic environments and transition those technologies to other Programs of Record to enhance the capability of the Joint Forces.



JPL CBRN INFORMATION MANAGEMENT/INFORMATION TECHNOLOGY (JPL CBRN IM/IT)

JPL CBRN IM/IT provides enterprise warning and reporting, hazard prediction and decision support capabilities for the collection, analysis and dissemination of CBRN defense information. JPL CBRN IM/IT capabilities provide battlespace awareness of CBRN threats via integrated early warning, DOD accredited hazard prediction models, and consequence management, course-of-action analysis, and decision support tools. JPL CBRN IM/IT is uniquely suited to provide Joint Service CBRN defense capabilities based on expertise in modeling, simulation and systems integration, and through leveraging our partnership with the Navy's PEO C4I and our close working relationship with the Naval Information Warfare Systems Command.



JPL CBRND ENABLING BIOTECHNOLOGIES (JPL CBRND EB)

JPL CBRND EB provides capabilities, infrastructure, and support for accelerated medical countermeasure development, manufacturing, testing, and deployment through a network of partnerships to address known, emerging, and engineered threats. During a crisis response, EB will play a leading role in centrally integrating capabilities to progress rapidly from "Information to Injection," including threat identification and characterization, MCM development and manufacturing, non-clinical and clinical testing, and fielding. EB brings a full suite of capabilities to support accelerated MCM development for the Warfighter, with an emphasis on efficiency and operational relevance.

JPEO-CBRND ORGANIZATION LEADERSHIP



CBRN INTEGRATION

Enable the investment in and development of mission-based capability sets within the portfolio through an integrated architecture of current and emerging capabilities, threats, requirements and user engagements.

- EXPERIMENTATION
- STRATEGIC ENGAGEMENT
- ENTERPRISE ARCHITECTURE
- SYSTEMS ENGINEERING
- EMERGING THREATS
- EMERGING CAPABILITIES

STRATEGIC OBJECTIVES



FOCUS ON END-USER AND SUPPORT TO OPERATIONAL FORCES



PORTFOLIO INSIGHT



TALENT MANAGEMENT



BUY SMART, MANAGE SMART



ACQUISITION REFORM

NATIONAL DEFENSE STRATEGY OBJECTIVES:

- BUILD A MORE LETHAL FORCE
- BUILD PARTNERSHIPS
- REFORM OUR BUSINESS PRACTICES

CBRN ANALYTICS

Strategically align policy, people, process, data and technology to enable leaders at all levels to assess and respond to the health and risks of the portfolio necessary to achieve strategic goals.

- PORTFOLIO ANALYSIS
- PLANNING, PROGRAMMING, BUDGET
- AND EXECUTION SYNCHRONIZATION
- DATA MANAGEMENT AND GOVERNANCE
- ASSESSMENT AND PORTFOLIO INSIGHT
- COST, SCHEDULE AND PERFORMANCE TRADE-OFFS



JOINT PROJECT MANAGER CBRN PROTECTION

CAPABILITIES

FOR MORE INFORMATION CALL 703-617-2400

JPM CBRN PROTECTION



Chemical Biological Protective Shelter (CBPS)

Description: "The Chemical Biological Protective Shelter (CBPS) provides U.S. forces with a highly mobile, easy-to-use, self-contained and chemical biological (CB) hardened shelter.

Benefits to Warfighter: CBPS allows Forward Resuscitative Surgical Teams and Role/Echelon I and II forward deployed medical personnel to treat patients without the encumbrance of individual protective clothing and equipment in a chemical and/or biological environment.

Program Status:

Projected Activities:




Decontamination Family of Systems Contamination Indicator Decontamination Assurance System (DFoS CIDAS)

Description: Contamination Indicator Decontamination Assurance System

Benefits to Warfighter: Increased decontamination efficiency and reduced logistics burden (e.g. water, manpower, and decontaminants) population groups through a standardized, modular system scalable to increase capability.

Program Status:

Projected Activities:



Joint Biological Agent Decontamination System (JBADS)

Description: The Joint Biological Agent Decontamination System will provide the capability to conduct biological warfare agent decontamination of the interior and exterior of aircraft to safe levels, to allow more rapid return to service.

Benefits to Warfighter: Decontaminates biologically decontaminated aircraft to facilitate return to service and enable mission continuation.

Program Status:

- FY17: Milestone B

Projected Activities:

- FY22: Initial Operational Capability

- FY22: Milestone C

- 2QFY24: Full Operational Capability

JPM CBRN PROTECTION



Joint Expeditionary Collective Protection (JEC)

Description: JEC is a family of systems that will allow the application of Collective Protection to transportable soft-side shelters, enclosed spaces of opportunity, and in remote austere locations as a standalone resource.

Benefits to Warfighter: JEC is a family of systems that protects personnel and infrastructure from chemical, biological, radiological and toxic industrial material contamination on the battlefield and during military operations other than war.

Program Status:

- FY06: Milestone A
- FY08: Milestone B
- FY13: Milestone C

Projected Activities:

- 4QFY22: Initial Operational Capability
- FY28: Full Operational Capability



Joint Service Aircrew Mask Rotary Wing (JSAM RW)

Description: The Joint Service Aircrew Mask Rotary Wing variant provides head, eye, respiratory and chemical biological (CB) protection for general purpose rotary wing aircrew except the AH-64 Apache and the V-22 Osprey.

Benefits to Warfighter: The JSAM RW is capable of being donned and doffed while in flight and decreases thermal burden compared to legacy systems. The mask allows Warfighters to survive and maintain operations in a chemical and biological threat environment.

Program Status:

- FY00: Milestone A
- FY03: Milestone B
- FY15: Milestone C
- FY19: Initial Operational Capability

Projected Activities:

- 4QFY24: Full Operational Capability (USN/USMC)



Joint Service Aircrew Mask Strategic Aircraft (JSAM SA)

Description: The JSAM SA mask will provide individual respiratory, ocular, and percutaneous protection of chemical and biological warfare agents, and select toxic industrial chemicals for USAF, USN, USMC, and USA strategic aircrew.

Benefits to Warfighter: Allows fixed-wing aircrew of non-ejection aircraft to survive and maintain operations in a chemical and biological threat environment.

Program Status:

- FY17: Milestone C

Projected Activities:

- FY20: Initial Operational Capability
- Mar 2025: Full Operational Capability

JPM CBRN PROTECTION



Joint Service Aircrew Mask Tactical Aircraft (JSAM TA)

Description: Joint Service Aircrew Tactical Aircraft is a lightweight, protective mask system providing CB Head, Eye, and Respiratory protection for aircrew of high performance, ejection seat tactical aircraft.

Benefits to Warfighter: Allows fixed-wing aircrew of high performance ejection seat tactical aircraft to survive and maintain operations in a chemical and biological threat environment.

Program Status:

- FY19: Milestone C

Projected Activities:

- FY21: Initial Operational Capability
- 4QFY24: Full Operational Capability (USN/USMC)



Joint Service General Purpose Mask (JSGPM)

Description: Joint Service General Purpose Mask

Benefits to Warfighter: Allows Warfighters to survive and maintain ground operations in a chemical and biological threat environment.

Program Status:

Projected Activities:



Mass Personnel Decontamination (MPD)

Description: The MPD shall provide Warfighters with the capability to reduce the hazards associated with mass casualty decontamination efforts for protected and unprotected personnel, casualties and Contaminated Human Remains (CHR) potentially exposed to CBRN hazards. The MPD will consist of a standardized, modular system using a scalable approach in order to increase capability.

Benefits to Warfighter: MPD reduces and limits the spread of contamination among potentially contaminated population groups through a standardized, modular system scalable to increase capability.

Program Status:

Projected Activities:

JPM CBRN PROTECTION



Uniform Integrated Protection Ensemble Family of Systems (UIPE FoS)

Description: Uniform Integrated Protection Ensemble Increment 2

Benefits to Warfighter: Provide individual protective capabilities through reduction of physiological and psychological burdens associated with the weight, bulk, thermal strain, and encumbrance of wearing CBRN protective gear.

Program Status:

Projected Activities:



JOINT PROJECT MANAGER CBRN MEDICAL

CAPABILITIES



FOR MORE INFORMATION CALL 301-619-7400

JPM CBRN MEDICAL



Advanced Anticonvulsant System (AAS)

Description: The Advanced Anticonvulsant System (AAS) advanced development will treat seizures caused by exposure to nerve agents via intramuscular injection of midazolam in an autoinjector.

Benefits to Warfighter: The AAS will provide life-saving anticonvulsant medical countermeasures against chemical nerve agents.

Program Status:

- FY03: Milestone A
- FY07: Milestone B
- FY13: Milestone C

Projected Activities:

- FY23: Initial Operational Capability
- FY25: Full Operational Capability




Alternative Autoinjector (AUTOINJ)

Description: AUTOINJ establishes additional manufacturers to fielded nerve agent antidote autoinjectors. Efforts expand the industrial manufacturing base and provide additional suppliers for life saving medical countermeasures to protect the Warfighter and Nation.

Benefits to Warfighter: Provides near- and long-term reliable sources for nerve agent antidote autoinjectors across the US government enterprise. Autoinjector efforts will integrate future countermeasures in development, modernize existing delivery platforms, and meet current FDA guidelines for drug delivery devices.

Program Status:

Projected Activities:



Antiviral Therapeutics Program (AV TX)

Description: The goal of the AVTX-Filovirus program is to develop an antiviral agent with broad-spectrum activity against EBOV and other filoviruses.

Benefits to Warfighter: AV TX will protect and sustain the Warfighter following exposure and infection.

Program Status:

- FY19: Milestone B

Projected Activities:

- 1QFY22: Milestone C
- FY23: Initial Operational Capability
- FY28: Full Operational Capability

JPM CBRN MEDICAL



Countermeasures for Multi-Drug Resistance-Bacterial (CMDR-B)

Description: Countermeasures for Multi-Drug Resistant-Bacteria

Benefits to Warfighter: Provides therapeutic solutions to counter traditional, emerging and engineered biological threats.

Program Status:

Projected Activities:



Improved Nerve Agent Treatment System-Oxime (INATS OX)

Description: Improved Nerve Agent Treatment System: Oxime

Benefits to Warfighter: INATS contains a centrally acting component that readily crosses the blood-brain barrier providing greater central nervous system protection against nerve agent exposure. Combined with a broader spectrum improved oxime, INATS will provide service members greater survivability on the modern battlefield.

Program Status:

Projected Activities:



Next Generation Diagnostics System 1 (NGDS 1)

Description: The Next Generation Diagnostic System I (NGDS-1) will identify biological hazards in human clinical specimens and provide diagnostic information to facilitate delivery of appropriate MCMs.

Benefits to Warfighter: NGDS will be employed in US Army (Role 3), US Air Force (Role 3) and US Navy (Role 2 and 3) deployable Combat Health Support units, with applicability to routine healthcare at higher echelons. NGDS will support accurate patient treatment, force health protection and CBRN situational awareness.

Program Status:

Projected Activities:

- FY12: Milestone A
- FY17: Milestone C

JPM CBRN MEDICAL



Next Generation Diagnostics System 2 (NGDS 2)

Description: NGDS FoS provides diagnostic capability increments for various CBR threats. NGDS Inc1 improves diagnostics for deployable & lab-based units, w/improved operational suitability & affordability over legacy systems, providing FDA-cleared BWA & infectious disease IVD assays on a commercial device. NGDS2 will complement Inc1, w/diagnostics for unmet bio pathogen/toxin threats, + chem or rad exposure, to suffice lower echelons of care. NGDS2 MPDS expands bio breadth/depth, suitable for use far forward

Benefits to Warfighter: NGDS 2 provides the far-forward, individual warfighter with an immediate medical diagnostic capability to diagnose potential nerve agent exposure before symptoms present themselves. This capability will inform medical treatment and Commander force protection decisions, increasing individual and unit survival.

Program Status:

Projected Activities:



Next Generation Diagnostics System 2-Chemical Diagnostics (NGDS 2 ChemDx)

Description: The Next Generation Diagnostic System 2 - Chemical Diagnostics (NGDS-2 ChemDx) will provide far-forward, immediate medical diagnostic capability for nerve agent exposure.

Benefits to Warfighter: NGDS 2 ChemDx provides the far-forward, individual warfighter with an immediate medical diagnostic capability to diagnose potential nerve agent exposure before symptoms present themselves. This capability will inform medical treatment and Commander force protection decisions, increasing individual and unit survival.

Program Status:

- FY17: Milestone A

Projected Activities:

- FY21: Milestone B
- FY24: Milestone C
- FY26: Initial Operational Capability
- FY28: Full Operational Capability



Next Generation Diagnostics System 2-Man Portable Diagnostic System (NGDS 2 MPDS)

Description: Next Generation Diagnostic System 2 - Man Portable Diagnostic System (NGDS-2 MPDS) is a portable diagnostic device and assays to diagnose diseases in austere, far-forward environments.

Benefits to Warfighter: The MPDS will provide earlier patient diagnosis and improve decision support for treatment and evacuation, in order to help mitigate the effects of exposure to unknown infectious disease and biological agents.


Program Status:

- FY19: Milestone B

Projected Activities:

- FY21: Milestone C

JPM CBRN MEDICAL



Rapid Opioid Countermeasure System (ROCS)

Description: The Rapid Opioid Countermeasure System (ROCS) program will provide a medical countermeasure against operational exposure to opioids.

Benefits to Warfighter: ROCS allows impacted service members to remain ambulatory in order to move to higher levels of care.

Program Status:

Projected Activities:



Western, Eastern, and Venezuelan Equine Encephalitis Vaccine (VAC WEVEE)

Description: The Medical Countermeasure System-Joint Vaccine Acquisition Program (MCS-JVAP) is developing a new vaccine for the Department of Defense intended to protect against aerosol exposure to strains of alphavirus: Western, Eastern and Venezuelan Equine Encephalitis (WEVEE) viruses. The initial development effort is for the indication against the Venezuelan Equine Encephalitis virus. The WEVEE viruses are highly infectious or highly lethal depending on the strain.

Benefits to Warfighter: Protects Warfighters against aerosolized alphavirus (including Venezuelan, Eastern and Western equine encephalitides) for which there is no currently licensed vaccine or therapeutic

Program Status:

Projected Activities:



JOINT PROJECT MANAGER CBRN SENSORS

CAPABILITIES



FOR MORE INFORMATION CALL 410-417-0228

JPM CBRN SENSORS



Aerosol Vapor Chemical Agent Detector (AVCAD)

Description: Aerosol & Vapor Chemical Agent Detector

Benefits to Warfighter: AVCAD provides a man-portable, sensitive aerosol and vapor chemical detection capability.

Program Status:

- FY14: Milestone A
- FY18: Milestone B

Projected Activities:

- FY21: Milestone C
- 2QFY24 - 4QFY24: Initial Operational Capability
- FY30: Full Operational Capability



Analytical Laboratory System Modification (ALS MOD)

Description: ALS MOD addresses critical analytical equipment obsolescence and system functionality for the National Guard Bureau (NGB) Weapons of Mass Destruction - Civil Support Teams (WMD-CSTs). ALS MOD is modular, scalable, and adaptable to various environmental conditions. Supports the specific mission and CONOPS of the gaining unit and is able to detect CBR material in environmental samples.

Benefits to Warfighter: The ALS MWO addresses ALS Increment 1 obsolescence issues and will optimize the Warfighter's ability to analyze data by providing enhanced human factors and engineering controls, a larger shelter and work space, upgraded software, larger databases to help identify unknowns, and improved process flow integration.

Program Status:

Projected Activities:

- FY22: Full Operational Capability



CBRN Sensor Integration on Robotic Platforms (CSIRP)

Description: CBRN Sensor Integration on Robotic Platforms (CSIRP) is a prototyping and fielding effort that will focus on repackaging and integrating modular CBRN sensor solutions to enhance Unmanned Air Systems (UAS) and Unmanned Ground Vehicles (UGV) Programs of Record (PORs) to provide situational awareness across the echelons of com

Benefits to Warfighter: CSIRP allows Warfighters greater freedom to maneuver and operate on the battlefield and provides increased decision space for Commanders at all echelons.

Program Status:

Projected Activities:

JPM CBRN SENSORS



Chemical Biological Radiological Nuclear Dismounted Reconnaissance Systems (CBRN DRS)

Description: The Chemical Biological Radiological Nuclear Dismounted Reconnaissance Systems (CBRN DRS) provides CBRN Warfighters with a comprehensive suite of detection/identification, protection, sample collection, hazard marking, decontamination, and support capabilities to characterize sites during

Benefits to Warfighter: CBRN DRS provides a comprehensive, all-hazards dismounted reconnaissance and site assessment capability to protect against, detect, and decontaminate chemical warfare agents, biological warfare agents, toxic industrial chemicals, and other hazards. SEPs will provide enhanced detection, protection, and situational awareness.

Program Status:

- FY11: Milestone B
- FY13: Milestone C

Projected Activities:

- FY22: Full Operational Capability
- FY26: Initial Operational Capability
- FY31: Full Operational Capability




Compact Vapor Chemical Agent Detector (CVCAD)

Description: Compact Vapor Chemical Agent Detector

Benefits to Warfighter: CVCAD alerts Warfighters to the presence of chemical vapor hazards and is applicable to man-worn and unmanned applications.

Program Status:

Projected Activities:



Enhanced Capability Demonstration Integrated Early Warning (ECD IEW)


Description: Enhanced Capability Demonstration Integrated Early Warning

Benefits to Warfighter: The CBRN IEW ECD is shaping the future of CBRN early warning by influencing the development of material solutions and capabilities to achieve the Warfighter vision of CBRN IEW.

Program Status:

Projected Activities:

JPM CBRN SENSORS



Enhanced Maritime Biological Detection (EMBD)

Description: Enhanced Maritime Biological Detection

Benefits to Warfighter: EMBD improves the Warfighter's confidence of biological detection.

Program Status:

- FY18: Milestone B
- FY20: Milestone C

Projected Activities:

- FY22: Initial Operational Capability
- FY28: Full Operational Capability



Joint Biological Tactical Detection System (JBTDs)

Description: Joint Biological Tactical Detection System

Benefits to Warfighter: The JBTDs' ability to detect, collect, and identify biological warfare agents at very low concentrations gives Warfighters additional time to make decisions and take action to prevent or reduce the risk of exposure.

Program Status:

- FY14: Milestone B

Projected Activities:

- FY22: Milestone C
- FY23: Initial Operational Capability



Joint Chemical Agent Detector M4A1 (JCAD M4A1)

Description: Joint Chemical Agent Detector M4A1

Benefits to Warfighter: The JCAD is a compact chemical warfare agent point detector that protects Warfighter life and health by providing enough warning to take any necessary protective measures.

Program Status:

Projected Activities:

JPM CBRN SENSORS



Joint Chemical Agent Detector Solid Liquid Adapter (JCAD SLA)

Description: Develop an adaptor to the M4A1 JCAD that allows solid and liquid sample introduction, loads solid and liquid detection libraries, and does not change M4A1 JCAD operation upon ejection from the adaptor.

Benefits to Warfighter: The JCAD SLA augments the currently fielded chemical vapor detection capability by providing trace (non-visible) detection of fourth generation agents, VX, pharmaceutical based agents, and explosive chemicals.

Program Status:

Projected Activities:



Joint Personal Dosimeter-Individual (JPD-I)

Description: The Joint Personal Dosimeter-Individual (JPD-I) is intended to replace DoDs legacy dosimeters (the Navys IM-270 and the Armys PDR-75 Series Systems). The JPD will provide a sensor to record and retrieve a Service members radiation exposure from occupational to tactical levels.

Benefits to Warfighter: JPD-I will be a National Voluntary Laboratory Accreditation Program that will allow dose of record to be obtained for a Warfighter's medical records.

Program Status:

- FY17: Milestone C

Projected Activities:

- FY21: Initial Operational Capability
- FY41: Full Operational Capability



Man-portable Radiological Detection System (MRDS)

Description: Man-portable Radiological Detection System

Benefits to Warfighter: MRDS increases the Warfighter's awareness of radiological threats at the tactical level.

Program Status:

- FY18: Milestone C

Projected Activities:

- FY24: Initial Operational Capability
- FY26: Full Operational Capability

JPM CBRN SENSORS



Multi-Phase Chemical Agent Detector (MPCAD)

Description: The MPCAD is a 2-man portable system that will conduct real-time, near-laboratory grade analysis of solid, liquid, and vapor samples collected by the operator in a contaminated area. The MPCAD results will support the Commander's decisions regarding maneuver, protection, decontamination, and treatment measures.

Benefits to Warfighter: MPCAD provides a higher fidelity analysis of samples collected in the field than the currently fielded detectors to enable Commanders to make more informed decisions.

Program Status:

- FY14: Milestone A
- FY18: Milestone B

Projected Activities:

- FY22: Milestone C
- FY24: Initial Operational Capability
- FY30: Full Operational Capability



Radiological Detection System (RDS)

Description: Radiological Detection System

Benefits to Warfighter: The RDS will provide Warfighters with an understanding of their total exposure to various types of radiation.

Program Status:

- FY14: Milestone A
- FY21: Milestone C

Projected Activities:

- FY22: Initial Operational Capability
- FY23: Full Operational Capability



Reactive Chemistry Orthogonal Surface and Environmental Threat Ticket Array (ROSETTA)

Description: Reactive-Chemistry Orthogonal Surface and Environmental Threat Ticket Array

Benefits to Warfighter: ROSETTA quickly detects hazards and gives the Warfighter additional confidence of a liquid chemical hazard.

Program Status:

Projected Activities:

JPM CBRN SENSORS



Screening Obscuration Module (SOM)

Description: The Screening Obscuration Module (SOM) is a modular medium-area and duration screening obscuration capability that is located at the small element level of conventional force units and is employed at the tactical in a mounted or dismounted configuration.

Benefits to Warfighter: The SOM increases Soldier protection levels of maneuver and platform survivability by degrading an enemy's ability to detect US targets.

Program Status:

- FY06: Milestone A

Projected Activities:

- SOM program will transition from EMD to the Production and Deployment phase in FY20



JOINT PROJECT LEAD CBRN SPECIAL OPERATIONS FORCES

CAPABILITIES

FOR MORE INFORMATION CALL 703-617-2400

JPL CBRN SPECIAL OPERATIONS FORCES



Joint Handheld Bio-Agent Identifier (JHBI)

Description: JHBI provides the capability to rapidly and accurately identify bio-agents at the point of contact in a handheld Polymerase Chain Reaction (PCR) device that includes integrated/automated sample preparation (ISP).

Benefits to Warfighter: Lowers burden of portable biological detection capability and improves Warfighter awareness of the presence of biological agents by rapidly and accurately identifying threats with a handheld polymerase chain reaction device.

Program Status:

Projected Activities:

- 3QFY20: Milestone C



Uniform Integrated Protection Ensemble 1 (UIPE 1)

Description: Uniform Integrated Protection Ensemble Increment 1

Benefits to Warfighter: UIPE Increment 1 reduces the physiological and psychological burdens associated with the weight, bulk, thermal strain, and encumbrance of wearing CBRN protective gear, increasing warfighter operational performance in a CBRN environment.

Program Status:

Projected Activities:

- FY13: Milestone C



JOINT PROJECT LEAD CBRN INFORMATION MANAGEMENT/ INFORMATION TECHNOLOGY

CAPABILITIES

FOR MORE INFORMATION CALL 619-221-7284

JPL CBRN INFORMATION MANAGEMENT/INFORMATION TECHNOLOGY



Chemical Biological Radiological Nuclear Information Systems (CBRNIS)

Description: Chemical, Biological, Radiological, and Nuclear Defense Information System provides a web-based capability that allows users to collect, collaborate, and disseminate CBRN hazard data for greater situational awareness of the CBRN environment and aid in decision support.


Benefits to Warfighter: CBRN IS provides a collaborative cloud-hosted environment that allows users to collect and disseminate CBRN warning and reporting data, provide detailed CBRN hazard predictions, aid in decision support, and make relevant CBRN defense information available in near-real-time. CBRN IS makes decision aids accessible through a web browser, simplifying interoperability, reducing integration and deployment costs, and increasing cybersecurity protection.

Program Status:

- FY18: Limited Deployment Decision on milCloud
- FY19: Full Deployment on milCloud
- FY20: Deployment on CENTRIXS-K

Projected Activities:

- FY23: Transition to Modernized CBRN IS



JOINT PROJECT LEAD CBRND ENABLING BIOTECHNOLOGIES

CAPABILITIES

FOR MORE INFORMATION CALL 301-619-3952

JPL CBRND ENABLING BIOTECHNOLOGIES



Chemical Biological Incident Preparedness and Response ADM (CBIPRADM)

Description: The DoD-ADM allows the DoD to quickly develop and manufacture medical countermeasures to protect and treat US forces in the event of a CBRN event or an infectious disease outbreak. The ADM is a contractor-owned, contractor-operated facility that fills a critical infrastructure gap in the nation's medical countermeasures manufacturing capacity. The DoD-ADM is a state-of-the-art biopharmaceutical manufacturing facility that utilizes both single-use and stainless steel manufacturing technologies. The facility is 183,000 square feet and is compliant with both the Food and Drug Administration's current Good Manufacturing Practices and the Center for Disease Control and Prevention's Biological Safety Level 3 requirements.

Benefits to Warfighter: Provides an agile, robust, and sustainable US-based facility that is capable of rapidly developing and manufacturing medical countermeasures for the warfighter.



Defense Biological Products Assurance Program (DBPAP)

Description: DBPAP provides characterized, standardized, high quality biological assays and reagents to the DoD, first responders, and other government agencies. DBPAO products support fielded biological agent detection capabilities as well as research and development of new technologies. The DPBAO Targeted Acquisition of Reference Materials Augmenting Capabilities (TARMAC) initiative is also involved in identifying emerging threats throughout the world. The DBPAO provides a unique capability.

Benefits to Warfighter: DBPAP provides a capability for early detection of a biological agent and emerging or reemerging infectious disease outbreaks and enables treatment of exposed Warfighters.



Medical Countermeasure Platform Technologies (MCMPT)

Description: Medical Countermeasure Platform Technologies (MCMPT) will leverage platform technologies to streamline and accelerate the MCM delivery to the Force by reducing developmental risk. A subset of these technologies will be adapted to deliver a rapid response capability to novel and emerging threats. The first platform being established as part of an Advanced Technology Demonstration (ATD) is the Advanced Development and Manufacturing Antibody Technologies (ADAMANT). A second platform technology will be established which will focus on a vaccine platform capability. The Agile Medical Paradigm (AMP) is the CBPD's strategic framework to accelerate the delivery of MCMs. To achieve this goal the DOD is establishing a medical countermeasures platform (MCMPT) capability. The goal of the MCMPT is to counter a variety of threat agents using standardized discovery, design, manufacturing, and testing processes to reduce the MCM development risks. Efforts will center on leveraging the DoD's Advanced Development Manufacturing (ADM) facility and developing robust manufacturing processes.


Benefits to Warfighter: Accelerates medical countermeasure delivery to the Warfighter and adapts a subset of capabilities and technologies to support a rapid response capability for novel and emerging threats.



LEGACY AND SUSTAINMENT CAPABILITIES




JPL CBRN INFORMATION MANAGEMENT/INFORMATION TECHNOLOGY



Joint Effects Model (JEM)

Description: JEM is a web-based software application that models and simulates the effects of CBRN weapon strikes and incidents. JEM accurately models and predicts the time-phased impact of CBRN and toxic industrial hazard (TIH) events and effects. JEM integrates with operational and tactical command and control systems and communicates with associated weather and intelligence systems.


Benefits to Warfighter: JEM provides warfighters the only DoD operational tested and accredited modeling capability that predicts high-fidelity downwind hazard areas and effects associated with the release of CBRN and TIH. Its models provide enhanced situational awareness of the battlespace and deliver near-real-time hazard information. JEM provides critical information to the decision-makers working to minimize CBRN and TIH effects on current operations and save lives.



Joint Warning and Reporting Network (JWARN)

Description: JWARN is a computer-based application integrating CBRN data and sensor information into joint and service command and control systems for battlespace situational awareness. JWARN takes the place of manual processes for reporting an incident, generating a hazard plot, and warning affected forces.

Benefits to Warfighter: JWARN significantly reduces the time from discovering an imminent CBRN threat to being able to warn forces on the ground. In less than two minutes, JWARN can provide enhanced situational awareness throughout the area of operations, directly supporting execution of warfighter battle management tasks.



Global Biosurveillance Portal (GBSP)

Description: GBSP is a mature, unclassified, web-based system capable of providing a near real-time common operating environment in support of civilian-military coordination at the strategic, operational, and tactical levels. Although originally designed for US Special Operations Command Force Health Protection and medical disciplines, it has strong capabilities to support CBRN and emergency/consequence management communities. GBSP users leverage a versatile group structure which allows for compartmentalized information sharing between the DoD, US Government interagency entities, and in the future with foreign partner nations.

Benefits to Warfighter: GBSP improves situational awareness of potential CBRN hazards, allowing warfighters and public health personnel worldwide to identify health risks early, and to quickly respond to, limit, or eliminate the risks of those threats to the joint force..

JPL CBRND ENABLING BIOTECHNOLOGIES



Special Immunization Program (VAC SIP)

Description: SIP offers selected legacy vaccines to laboratory workers at risk for pathogen and toxin exposure. The seven vaccines in the SIP portfolio protect both military and civilian researchers from tularemia, Eastern Equine Encephalitis, Western Equine Encephalitis, Venezuelan Equine Encephalitis and Q-Fever. The CBRND is exploring ways to leverage the SIP to support an interim fielding program for products under development. Efforts include Good Manufacturing Practices compliant storage and annual potency and stability testing to support the FDA reporting requirements. This Department of Defense program supports other federal agencies as well as academic and industry partners.

Benefits to Warfighter: Supports CBRND Core Capabilities and Advanced Development Effort. Only vaccines currently available in the U.S. for these high consequence, low probability threats.




Joint Mobile Emerging Disease Intervention Clinical Capability (JMEDICC)

Description: JMEDICC is a platform geared towards execution of clinical trials in a filovirus outbreak setting in order to obtain data to support potential Interim Fielding Capabilities approval and licensure by the Food and Drug Administration. JMEDICC has a fixed hub site at the Fort Portal Regional Referral Hospital in western Uganda that can be extended to conduct field clinical trials throughout Uganda. This effort enhances clinical research for filovirus treatments in a country at risk of outbreaks through prepositioned staff, infrastructure, logistics, and pre-approved Investigational New Drug study protocols.

Benefits to Warfighter: JMEDICC facilitates rapid medical response to an emerging infectious disease outbreak.

JPM CBRN PROTECTION



Chemical Biological Aircraft Survivability Barrier (CASB)

Description: CASB supports the warfighter by enabling the use of airlift aircraft forefiltration of chemically or biologically contaminated personnel and cargos while preserving the aircraft for continued unrestricted operations without need for decontamination.

Benefits to Warfighter: CASB reduces the time and logistical burden required for extensive decontamination and helps maintain force readiness by preventing or limiting Warfighter and multi-service aircraft exposure to chemical and biological threats.



M41A1 Protective Assessment Test System (PATs)

Description: The M41A1 PATs enables quantitative protective mask fit assessment and validation. The legacy M41 PATs critical electronic parts are no longer being manufactured. Modernization is necessary to overcome shortage of calibration and repair maintenance parts and sustain capability for man-mask fit testing.

Benefits to Warfighter: The M41A1 PATs enables man-mask system fit factor testing to provide a “go/no-go” check of mask fit on the user, which includes the U.S. Army, Surety Sites and DoD Components.



Joint Service Equipment Wipe (JSEW)

Description: JSEW provides immediate and operational decontamination capabilities for sensitive and non-sensitive equipment that have been exposed to traditional and non-traditional chemical contamination, replacing/augmenting the M295 legacy decontamination kit.

Benefits to Warfighter: The first decontamination capability available to Warfighters that is non-destructive to sensitive equipment. JSEW will be applied directly to the contaminated surface and is capable of removing gross contamination and reducing contact hazard within five minutes without leaving a residue.

JPM CBRN MEDICAL

**Botulinum Toxin Vaccine (VAC BOT)**

Description: Botulinum toxins are the most potent, naturally-occurring toxins in the world and are odorless, tasteless, and invisible to the human eye. If untreated, exposure to botulinum toxin has a mortality rate of one hundred percent. There are currently no FDA licensed vaccines, rapid medical diagnostics, or real-time warning or detection systems for use against aerosolized botulinum toxins. This vaccine protects against exposure to botulinum toxin serotypes A and B.

Benefits to Warfighter: Protects the Warfighter against aerosolized exposure to botulinum toxin serotypes A and B eliminating weaponized botulinum A and B as a threat.

**Plague Vaccine (VAC PLG)**

Description: Yersinia pestis (plague) is a bacteria that causes a life-threatening disease that is nearly always fatal in its pneumonic (spread by aerosol) form if left untreated. Plague can spread from person-to-person with close contact. There are no FDA licensed vaccines for use against aerosolized plague. This vaccine protects against aerosol exposure to plague.

Benefits to Warfighter: Protects the Warfighter against aerosolized exposure to plague, eliminating weaponized plague as a threat.

**Filovirus Vaccine (VAC FILO)**

Description: FiloV is developing filovirus vaccines for the DoD to protect against aerosolized exposure to Sudan, Ebola, and Marburg viruses. The initial developmental increment will provide an effective prophylactic against Marburg viruses. Follow-on incremental development efforts will provide protection against aerosolized exposure to Sudan virus and Ebolavirus.

Benefits to Warfighter: Provides Warfighters protection against aerosolized exposure to Sudan, Ebola and Marburg viruses.

JPM CBRN SENSORS



Unified Command System (UCS)

Description: The UCS is a fully integrated mobile communications suite composed of a communications platform and a Command vehicle that is self-sufficient and highly interoperable by integrating commercial- and government-off-the-shelf military communications hardware. UCS provides communications interoperability with Federal, State, local and military emergency response elements. In addition to providing contingency response to WMD & CBRNE threats, the UCS can be used to support natural disaster response and high-profile political, cultural, and athletic events.

Benefits to Warfighter: UCS provides a critical reach back capability for Incident Commanders assessing an incident scene and advising responders. It also facilitates civilian responders’ access to DoD information. UCS satisfies the critical Key Performance Parameter of directed reach back communications for the Analytical Laboratory Modification Work Order and other Civil Support Team systems.



ACRONYM LIST



| ACRONYM | DEFINITION |
|------------|---|
| AAS | Advanced Anticonvulsant System |
| AUTOINJ | Alternative Autoinjector |
| ADMC | Advanced Development and Manufacturing Capabilities |
| ALS MOD | Analytical Laboratory System Modification |
| AVCAD | Aerosol Vapor Chemical Agent Detector |
| AV TX | Antiviral Therapeutics Program |
| BMO | Biosurveillance Management Office |
| CASB | Chemical Biological Aircraft Survivability Barrier |
| CB | Chemical Biological |
| CBIPR ADM | Chemical Biological Incident Preparedness and Response Advanced Development and Manufacturing |
| CBPS | Chemical Biological Protective Shelter |
| CBRN | Chemical, Biological, Radiological and Nuclear |
| CBRND | Chemical, Biological, Radiological and Nuclear Defense |
| CBRN DRS | Chemical Biological Radiological Nuclear Dismounted Reconnaissance Systems |
| CBRN IS | Chemical Biological Radiological Nuclear Information Systems |
| CHR | Contaminated Human Remains |
| CMDR-B | Countermeasures for Multi-Drug Resistance-Bacterial |
| CSIRP | CBRN Sensor Integration on Robotic Platforms |
| CVCAD | Compact Vapor Chemical Agent Detector |
| DAWIA | Defense Acquisition Workforce Improvement Act |
| DBPAO | Defense Biologics Product Assurance Offices |
| DBPAP | Defense Biological Products Assurance Program |
| DFoS CIDAS | Decontamination Family of Systems Contamination Indicator Decontamination Assurance System |
| EB | Enabling Biotechnologies |
| ECD IEW | Enhanced Capability Demonstration Integrated Early Warning |
| GBSP | Global Biosurveillance Portal |
| IM/IT | Information Management/Information Technology |
| INATS OX | Improved Nerve Agent Treatment System-Oxime |
| IS | Information Systems |
| ISP | Integrated/automated Sample Preparation |
| JBADS | Joint Biological Agent Decontamination System |
| JBTDS | Joint Biological Tactical Detection System |
| JCAD M4A1 | Joint Chemical Agent Detector M4A1 |
| JCAD SLA | Joint Chemical Agent Detector Solid Liquid Adapter |
| JECP | Joint Expeditionary Collective Protection |
| JEM | Joint Effects Model |
| JHBI | Joint Handheld Bio-Agent Identifier |
| JMEDICC | Joint Mobile Emerging Disease Intervention Clinical Capability |
| JPD-I | Joint Personal Dosimeter-Individual |
| JPEO-CBRND | Joint Program Executive Officer for Chemical, Biological, Radiological and Nuclear Defense |
| JPL | Joint Project Lead |
| JPM | Joint Project Manager |

| ACRONYM | DEFINITION |
|------------------|---|
| JWARN | Joint Warning and Reporting Network |
| JSAM RW | Joint Service Aircrew Mask Rotary Wing |
| JSAM SA | Joint Service Aircrew Mask Strategic Aircraft |
| JSAM TA | Joint Service Aircrew Mask Tactical Aircraft |
| JSEW | Joint Service Equipment Wipe |
| JSGPM | Joint Service General Purpose Mask |
| MCM | Medical Countermeasure |
| MCMP | Medical Countermeasure Platform Technologies |
| MCSJVAP | Medical Countermeasure System-Joint Vaccine Acquisition Program |
| MPCAD | Multi-Phase Chemical Agent Detector |
| MPD | Mass Personnel Decontamination |
| MRDS | Man-portable Radiological Detection System |
| NGB | National Guard Bureau |
| NGDS | Next Generation Diagnostics System |
| NGDS 2 ChemDx | Next Generation Diagnostics System 2 Chemical Diagnostics |
| NGDS 2 MPDS | Next Generation Diagnostics System 2-Man Portable Diagnostic System |
| PATS | Protective Assessment Test System |
| PCR | Polymerase Chain Reaction |
| POR | Programs of Record |
| PRISM | Platforms for Rapid Integrated Solutions for Medical Countermeasures |
| RADIAC | Radiation Detection, Indication and Computation |
| rBV A/B; VAC BOT | Recombinant Botulinum Vaccine |
| RDS | Radiological Detection System |
| rF1V | Recombinant Plague Vaccine |
| ROCS | Rapid Opioid Countermeasure System |
| ROSETTA | Reactive Chemistry Orthogonal Surface and Environmental Threat Ticket Array |
| S&T | Science and Technology |
| SEP | System Enhancement Package |
| SLA | Solid Liquid Adapter |
| SNAPP | Soman Nerve Agent Pretreatment Pyridostigmine |
| SOF | Special Operations Forces |
| SOM | Screening Obscuration Module |
| SSA | Software Support Activity |
| SSA-N | Small Scale Applicator-Nerve |
| SSD | Systems Support Directorate |
| SSU | Sensor Suite Upgrade |
| SUDV | Sudan Virus |
| TARMAC | Targeted Acquisition of Reference Materials Augmenting Capabilities |
| TEI | Test, Evaluation and Infrastructure |
| TIH | Toxic Industrial Hazard |
| UAS | Unmanned Air Systems |

| ACRONYM | DEFINITION |
|-----------|--|
| UCS | Unified Command System |
| UGV | Unmanned Ground Vehicles |
| UIPE | Uniform Integrated Protection Ensemble |
| UIPE FoS | Uniform Integrated Protection Ensemble Family of Systems |
| USSOCOM | U.S. Special Operations Command |
| VAC BOT | Botulinum Toxin Vaccine |
| VAC FILO | Filovirus Vaccine |
| VAC PLG | Plague Vaccine |
| VAC SIP | Special Immunization Program |
| VAC WEVEE | Western, Eastern, and Venezuelan Equine Encephalitis Vaccine |
| WMD-CST | Weapons of Mass Destruction Civil Support Team |
| WRAIR | Walter Reed Army Institute of Research |





www.jpeocbrnd.osd.mil

410-436-9000



@JPEOCBRND